See more : Edensoft Holdings Limited (1147.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Edoc Acquisition Corp. (ADOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edoc Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- China Dasheng Biotechnology Company (CDBT) Income Statement Analysis – Financial Results
- Stratim Cloud Acquisition Corp. (SCAQW) Income Statement Analysis – Financial Results
- ESG Core Investments B.V. (ESG.AS) Income Statement Analysis – Financial Results
- Bitcoin Generation Inc. (BTGN) Income Statement Analysis – Financial Results
- Seadrill Limited (SDRL) Income Statement Analysis – Financial Results
Edoc Acquisition Corp. (ADOC)
About Edoc Acquisition Corp.
Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.54M | 1.80M | 0.00 |
| Gross Profit | -2.54M | -1.80M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 1.80M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.54M | 1.80M | 89.34K |
| Other Expenses | 2.54M | -70.30K | -565.30K |
| Operating Expenses | 2.54M | 1.80M | -565.30K |
| Cost & Expenses | 2.54M | 1.80M | -565.30K |
| Interest Income | 314.16K | 20.87K | 8.68K |
| Interest Expense | 36.10K | 5.03K | 0.00 |
| Depreciation & Amortization | 2.54K | 1.80K | 268.02 |
| EBITDA | -5.14K | 898.22 | -1.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.54K | -1.80K | -268.02 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.14M | 898.22K | -1.43K |
| Income Before Tax | -7.69K | -899.88 | -1.70K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.14K | 898.22 | -1.43K |
| Net Income | -7.69K | -899.88 | -1.70K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 5.93M | 11.80M | 11.80M |
| Weighted Avg Shares Out (Dil) | 5.93M | 11.80M | 11.80M |
ADOCIA Announces the Release of its Universal Registration Document for the Year 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the filing of its...
ADOCIA annonce la mise à disposition de son Document d’Enregistrement Universel pour l’année 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce le dépôt...
ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports today its first quarter financial...
ADOCIA publie ses résultats financiers du premier trimestre 2023 et fait le point sur ses activités
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, publie ses résultats...
ADOCIA Announces Its Annual Shareholders’ Meeting to Be Held on May 11, 2023 in Paris
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its...
ADOCIA annonce la tenue de son assemblée générale annuelle le 11 mai 2023 à Paris
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce la tenue de...
Number of Shares and Voting Rights of ADOCIA as of March 31st, 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA, a French...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 mars 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA, 115, avenue Lacassagne, 69003 Lyon (Euronext Paris :...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 28 février 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA, 115, avenue Lacassagne, 69003 Lyon (Euronext Paris :...
Number of Shares and Voting Rights of ADOCIA as of February 28th, 2023
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA, a French...
Source: https://incomestatements.info
Category: Stock Reports